
Rezon Bio
European biologics CDMO for cost-efficient, end-to-end development and manufacturing.
European biologics CDMO offering end-to-end development and manufacturing across two GMP-certified sites in Poland, with capabilities from cell line development to commercial-scale production. Headquartered in Poland.
Modalities
Development & manufacturing
Structured CDMO capabilities from verified public sources.
Manufacturing (M)
Biologics / bioreactor infrastructure
- Expression systems
- Mammalian
- Bioreactor type
- Stainless Steel
- Max bioreactor scale
- Large commercial (≤10,000 L)
Regulatory clearances
Services
About this organization
Rezon Bio is a European biologics contract development and manufacturing organization (CDMO) specializing in cost-efficient, scalable solutions for biologics programs. The company operates two GMP-certified facilities in Poland, providing integrated services from early-stage development through commercial manufacturing.
Core Capabilities
- Process Development & Characterization: Scalable upstream and downstream biologics processes optimized for biosimilars and new biological entities (NBEs) from lab to commercial scale
- Analytical Capabilities: Phase-appropriate, method-qualified testing for product quality and release
- GMP Manufacturing: Flexible capacity at clinical and commercial scale, FDA and EMA approved
- Quality & Regulatory Affairs: Systems aligned with regulatory requirements, confirmed by successful inspections
- Technology Transfer, MSAT & PPQ: Strategic partnerships for fill/finish enabling "ready to fill" solutions
- Cell Line Development: End-to-end services from cell line development to commercial manufacturing
Facilities & Scale
The organization operates two sites: a clinical development and manufacturing center with medium-scale capacity, and a large state-of-the-art GMP facility offering commercial-scale manufacturing with 2,000L bioreactors.
Track Record
With over 13 years of biologics development experience, Rezon Bio has completed 12 technology transfers and produced 137 batches since 2024 with a 97% batch success rate. The company has passed 35+ audits from EMA, FDA, MHRA, and ANVISA. The workforce exceeds 1,100 employees, with 80% holding higher education degrees and 10% holding PhDs.
Certifications
Locations
Headquarters / Clinical Development & Manufacturing
Poland · Poland
Commercial Scale Manufacturing
Poland · Poland
Clinical Development & Manufacturing
Poland · Poland
Commercial Scale Manufacturing
Poland · Poland
Similar companies
Similar profiles by shared services, modalities, and capabilities.
WuXi Biologics- Cell-Line Development
- Upstream Processing
KBI Biopharma, Inc.- Cell-Line Development
- Upstream Processing
Lonza Cell & Gene Technologies- Regulatory Affairs
- Cell-Line Development
Enzene Biosciences- Cell-Line Development
- Process Development
Northway Biotech- Cell-Line Development
- Upstream Processing
GBI Biomanufacturing- Cell-Line Development
- Upstream Processing
Avid Bioservices- Cell-Line Development
- Upstream Processing
Validogen- Cell-Line Development
- Upstream Processing
View all alternatives →See similar CDMOs ranked by shared capabilities
Submit a verified review for this organization.
Markdown mirror: /companies/rezonbio.md